Search Results - "Latz, Jane E."

Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients by LATZ, Jane E, CHAUDHARY, Ajai, GHOSH, Atalanta, JOHNSON, Robert D

“…The objectives of these population pharmacokinetic analyses were to (1) assess the overall disposition of pemetrexed, (2) characterize between-patient and…”
Get full text

Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function by MITA, Alain C, SWEENEY, Christopher J, MOLPUS, Kathleen, LATZ, Jane E, SIMMS, Lorinda, CHAUDHARY, Ajai K, JOHNSON, Robert D, ROWINSKY, Eric K, TAKIMOTO, Chris H, BAKER, Sharyn D, GOETZ, Andrew, HAMMOND, Lisa A, PATNAIK, Amita, TOLCHER, Anthony W, VILLAHNA-CALERO, Mtguel, SANDLER, Alan, CHAUDHURI, Tuhin

“…This phase I study was conducted to determine the toxicities, pharmacokinetics, and recommended doses of pemetrexed in cancer patients with normal and impaired…”
Get full text

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer by TAKIMOTO, Chris H, HAMMOND-THELIN, Lisa A, WOOD, Leslie, SCHNECK, Karen B, CLARK, Romnee, ROWINSKY, Eric K, LATZ, Jane E, FORERO, Leonardo, BEERAM, Muralidhar, FOROUZESH, Bahram, DE BONO, Johann, TOLCHER, Anthony W, PATNAIK, Amita, MONROE, Pamela

“…Purpose: This phase I study evaluated the effect of folate supplementation on the toxicity, tolerability, and pharmacokinetics of pemetrexed in patients with…”
Get full text

A semimechanistic-physiologic population pharmacokinetic/ pharmacodynamic model for neutropenia following pemetrexed therapy by LATZ, Jane E, KARLSSON, Mats O, RUSTHOVEN, James J, GHOSH, Atalanta, JOHNSON, Robert D

“…The objectives of these analyses were to (1) develop a semimechanistic-physiologic population pharmacokinetic/pharmacodynamic (PK/PD) model to describe…”
Get full text

Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients by Latz, Jane E, Schneck, Karen Lee, Nakagawa, Kazuhiko, Miller, Mary Alice, Takimoto, Chris H

“…Purpose: The objectives of the analysis were to characterize the time course of neutropenia after pemetrexed administration using an established…”
Get full text

Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non–Small Cell Lung Cancer by Dickgreber, Nicolas J, Fink, Thomas H, Latz, Jane E, Hossain, Anwar M, Musib, Luna C, Thomas, Michael

“…Purpose: Pemetrexed is approved as monotherapy and in combination with cisplatin. The established combination dose was identified before the addition of folic…”
Get full text

Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy by LATZ, Jane E, RUSTHOVEN, James J, KARLSSON, Mats O, GHOSH, Atalanta, JOHNSON, Robert D

“…The objective of these analyses was to examine the effect of variations in the explanatory factors of neutropenic response, identified by…”
Get full text

Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer by SWEENEY, Christopher J, TAKIMOTO, Chris H, CHAUDHURI, Tuhin, SANDLER, Alan, MITA, Alain C, ROWINSKY, Eric K, LATZ, Jane E, BAKER, Sharyn D, MURRY, Daryl J, KRULL, James H, FIFE, Karen, BATTIATO, Linda, CLEVERLY, Ann, CHAUDHARY, Ajai K

“…Purpose: Pemetrexed is an antimetabolite that is structurally similar to methotrexate. Because nonsteroidal anti-inflammatory drugs (NSAID) impair methotrexate…”
Get full text

A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies by Rowinsky, Eric K, Beeram, Muralidhar, Hammond, Lisa A, Schwartz, Garry, De Bono, Johann, Forouzesh, Baharam, Chu, Quincy, Latz, Jane E, Hong, Shengyan, John, William, Nguyen, Binh

“…Purpose: The main objectives of this phase I and pharmacokinetic, open-label study were to characterize the principal toxicities and determine the maximum…”
Get full text

Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116 by Casey, Erin M, Harb, Wael, Bradford, Daniel, Bufill, Jose, Nattam, Sreenivasa, Patel, Jyoti, Fisher, William, Latz, Jane E, Li, Xiaochun, Wu, Jingwei, Hanna, Nasser

“…: Bevacizumab is approved in combination with chemotherapy as first-line treatment for non-small cell lung cancer (NSCLC). Preclinical data suggest that…”
Get more information

Pemetrexed Safety and Pharmacokinetics in Patients with Third-Space Fluid by DICKGREBER, Nicolas J, BENN SORENSEN, Jens, PAZ-ARES, Luis G, KJESTRUP SCHYTTE, Tine, LATZ, Jane E, SCHNECK, Karen B, ZHENG YUAN, SANCHEZ-TORRES, José Miguel

“…Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC)…”
Get full text

A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer by Clément-Duchêne, Christelle, Natale, Ronald B, Jahan, Thierry, Krupitskaya, Yelena, Osarogiagbon, Raymond, Sanborn, Rachel E, Bernstein, Eric D, Dudek, Arkadiusz Z, Latz, Jane E, Shi, Peipei, Wakelee, Heather A

“…Abstract Introduction Regardless of epidermal growth factor receptor (EGFR) mutation status, erlotinib improves survival for patients with advanced non-small…”
Get full text

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors by Padda, Sukhmani K., Krupitskaya, Yelena, Chhatwani, Laveena, Fisher, George A., Colevas, Alexander D., San Pedro-Salcedo, Melanie, Decker, Rodney, Latz, Jane E., Wakelee, Heather A.

“…Purpose Enzastaurin, an oral serine/threonine kinase inhibitor, targets the protein kinase C and AKT pathways with anti-tumor and anti-angiogenic effects…”
Get full text

Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients by Specenier, Pol M, Ciuleanu, Tudor, Latz, Jane E, Musib, Luna C, Darstein, Christelle L. S, Vermorken, Jan B

“…Purpose This phase I study characterized the pharmacokinetics of free and total platinum derived from cisplatin administered alone and in combination with…”
Get full text

Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity by McQuaid, Loretta A, Latz, Jane E, Clemens, James A, Fuller, Ray W, Wong, David T, Mason, Norman R

“…Two series of tetrahydroindazoles were synthesized and evaluated for dopaminergic activity. A number of these partial ergoline analogues possess substituents…”
Get full text